On this page you will find our recommendations sorted by BNF chapter.

Appraisal Reports are available to stakeholders on request.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net

Title Documents Decision Date

Updated

07/06/2022
Budesonide orodispersible for maintenance treatment of eosinophilic oesophagitis Recommendation Recommended as an option 07/06/2022
Infliximab biosimilars See Musculoskeletal and joint diseases recommendations Recommended as an option 02/06/2015
Infliximab Subcutaneous (Remsima®) Musculoskeletal and joint diseases recommendations Recommended as an option during Covid-19 Pandemic. 22/02/2022
Leukapheresis with Adacolumn™ for Inflammatory Bowel Disease (NETAG) Recommendation Not recommended 18/01/2011

Updated

31/01/2023
Transanal Irrigation Systems (TAIs) for neurogenic bowel dysfunction, chronic constipation, and chronic faecal incontinence NTAG Decision Summary Transanal irrigation systems - updated Nov 2022 - final Recommended for restricted use. Recommended as per NTAG Decision Summary in NENC Medicines Committee Recommendations from December 2022 https://northeastnorthcumbria.nhs.uk/about-us/publications/medicines-committee/ 15/11/2022